Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
8
INBS Quote, Financials, Valuation and Earnings
Last price:
$1.33
Seasonality move
:
-22.56%
Day range:
$1.24 - $1.36
52-week range:
$1.00 - $11.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.62x
P/B ratio:
0.96x
Volume:
136.2K
Avg. volume:
150.6K
1-year change:
-69.21%
Market cap:
$5.8M
Revenue:
$3.1M
EPS (TTM):
-$35.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INBS
Intelligent Bio Solutions
|
$1.4M | -- | 160.36% | -- | -- |
|
ADGM
Adagio Medical Holdings
|
-- | -- | -- | -- | -- |
|
AIMD
Ainos
|
-- | -- | -- | -- | -- |
|
LAB
Standard BioTools
|
$41M | -$0.08 | 52.67% | -88% | -- |
|
LNSR
LENSAR
|
$11.5M | -$0.30 | 23.5% | -48.57% | -- |
|
ZOM
Zomedica
|
-- | -- | 10.4% | -72% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INBS
Intelligent Bio Solutions
|
$1.33 | -- | $5.8M | -- | $0.00 | 0% | 0.62x |
|
ADGM
Adagio Medical Holdings
|
$1.75 | -- | $13.2M | -- | $0.00 | 0% | -- |
|
AIMD
Ainos
|
$0.45 | -- | $6.2M | -- | $0.00 | 0% | 33.57x |
|
LAB
Standard BioTools
|
$2.00 | -- | $744.5M | -- | $0.00 | 0% | 3.58x |
|
LNSR
LENSAR
|
$7.70 | -- | $89.4M | -- | $0.00 | 0% | 1.80x |
|
ZOM
Zomedica
|
$0.13 | -- | $122.8M | -- | $0.00 | 0% | 4.59x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INBS
Intelligent Bio Solutions
|
7.57% | 6.876 | 6.74% | 0.92x |
|
ADGM
Adagio Medical Holdings
|
-- | 0.626 | -- | -- |
|
AIMD
Ainos
|
20.03% | 0.945 | 81.11% | 0.22x |
|
LAB
Standard BioTools
|
10.14% | -0.573 | 7.68% | 3.33x |
|
LNSR
LENSAR
|
-- | 4.014 | -- | 1.95x |
|
ZOM
Zomedica
|
-- | 2.172 | -- | 9.83x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INBS
Intelligent Bio Solutions
|
$346.8K | -$2.7M | -161.24% | -176.44% | -306.38% | -$2.4M |
|
ADGM
Adagio Medical Holdings
|
-- | -$611.7K | -- | -- | -- | -$511.7K |
|
AIMD
Ainos
|
-$550 | -$3M | -45.16% | -52.95% | -15756.26% | -$1.5M |
|
LAB
Standard BioTools
|
$23.3M | -$24.3M | -39.17% | -48.03% | -54.03% | -$30.1M |
|
LNSR
LENSAR
|
$6.3M | -$1.2M | -56.16% | -56.16% | -9.2% | $3.1M |
|
ZOM
Zomedica
|
$5.1M | -$7.4M | -27.17% | -27.17% | -96.1% | -$5.9M |
Intelligent Bio Solutions vs. Competitors
-
Which has Higher Returns INBS or ADGM?
Adagio Medical Holdings has a net margin of -307.88% compared to Intelligent Bio Solutions's net margin of --. Intelligent Bio Solutions's return on equity of -176.44% beat Adagio Medical Holdings's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INBSIntelligent Bio Solutions39.76% -$8.40 $6.4M ADGMAdagio Medical Holdings-- -$0.03 -- -
What do Analysts Say About INBS or ADGM?
Intelligent Bio Solutions has a consensus price target of --, signalling upside risk potential of 802.26%. On the other hand Adagio Medical Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Intelligent Bio Solutions has higher upside potential than Adagio Medical Holdings, analysts believe Intelligent Bio Solutions is more attractive than Adagio Medical Holdings.
Company Buy Ratings Hold Ratings Sell Ratings INBSIntelligent Bio Solutions0 0 0 ADGMAdagio Medical Holdings0 0 0 -
Is INBS or ADGM More Risky?
Intelligent Bio Solutions has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adagio Medical Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock INBS or ADGM?
Intelligent Bio Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagio Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intelligent Bio Solutions pays -- of its earnings as a dividend. Adagio Medical Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INBS or ADGM?
Intelligent Bio Solutions quarterly revenues are $872.3K, which are larger than Adagio Medical Holdings quarterly revenues of --. Intelligent Bio Solutions's net income of -$2.7M is lower than Adagio Medical Holdings's net income of -$245.9K. Notably, Intelligent Bio Solutions's price-to-earnings ratio is -- while Adagio Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intelligent Bio Solutions is 0.62x versus -- for Adagio Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INBSIntelligent Bio Solutions0.62x -- $872.3K -$2.7M ADGMAdagio Medical Holdings-- -- -- -$245.9K
-
Which has Higher Returns INBS or AIMD?
Ainos has a net margin of -307.88% compared to Intelligent Bio Solutions's net margin of -15991.17%. Intelligent Bio Solutions's return on equity of -176.44% beat Ainos's return on equity of -52.95%.
Company Gross Margin Earnings Per Share Invested Capital INBSIntelligent Bio Solutions39.76% -$8.40 $6.4M AIMDAinos-29.07% -$0.33 $28.4M -
What do Analysts Say About INBS or AIMD?
Intelligent Bio Solutions has a consensus price target of --, signalling upside risk potential of 802.26%. On the other hand Ainos has an analysts' consensus of -- which suggests that it could fall by --. Given that Intelligent Bio Solutions has higher upside potential than Ainos, analysts believe Intelligent Bio Solutions is more attractive than Ainos.
Company Buy Ratings Hold Ratings Sell Ratings INBSIntelligent Bio Solutions0 0 0 AIMDAinos0 0 0 -
Is INBS or AIMD More Risky?
Intelligent Bio Solutions has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ainos has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.704%.
-
Which is a Better Dividend Stock INBS or AIMD?
Intelligent Bio Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ainos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intelligent Bio Solutions pays -- of its earnings as a dividend. Ainos pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INBS or AIMD?
Intelligent Bio Solutions quarterly revenues are $872.3K, which are larger than Ainos quarterly revenues of $20.7K. Intelligent Bio Solutions's net income of -$2.7M is higher than Ainos's net income of -$3.7M. Notably, Intelligent Bio Solutions's price-to-earnings ratio is -- while Ainos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intelligent Bio Solutions is 0.62x versus 33.57x for Ainos. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INBSIntelligent Bio Solutions0.62x -- $872.3K -$2.7M AIMDAinos33.57x -- $20.7K -$3.7M
-
Which has Higher Returns INBS or LAB?
Standard BioTools has a net margin of -307.88% compared to Intelligent Bio Solutions's net margin of -59.9%. Intelligent Bio Solutions's return on equity of -176.44% beat Standard BioTools's return on equity of -48.03%.
Company Gross Margin Earnings Per Share Invested Capital INBSIntelligent Bio Solutions39.76% -$8.40 $6.4M LABStandard BioTools51.73% -$0.07 $544.5M -
What do Analysts Say About INBS or LAB?
Intelligent Bio Solutions has a consensus price target of --, signalling upside risk potential of 802.26%. On the other hand Standard BioTools has an analysts' consensus of -- which suggests that it could grow by 54.17%. Given that Intelligent Bio Solutions has higher upside potential than Standard BioTools, analysts believe Intelligent Bio Solutions is more attractive than Standard BioTools.
Company Buy Ratings Hold Ratings Sell Ratings INBSIntelligent Bio Solutions0 0 0 LABStandard BioTools0 0 0 -
Is INBS or LAB More Risky?
Intelligent Bio Solutions has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.606, suggesting its more volatile than the S&P 500 by 60.617%.
-
Which is a Better Dividend Stock INBS or LAB?
Intelligent Bio Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intelligent Bio Solutions pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INBS or LAB?
Intelligent Bio Solutions quarterly revenues are $872.3K, which are smaller than Standard BioTools quarterly revenues of $45M. Intelligent Bio Solutions's net income of -$2.7M is higher than Standard BioTools's net income of -$26.9M. Notably, Intelligent Bio Solutions's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intelligent Bio Solutions is 0.62x versus 3.58x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INBSIntelligent Bio Solutions0.62x -- $872.3K -$2.7M LABStandard BioTools3.58x -- $45M -$26.9M
-
Which has Higher Returns INBS or LNSR?
LENSAR has a net margin of -307.88% compared to Intelligent Bio Solutions's net margin of -11.09%. Intelligent Bio Solutions's return on equity of -176.44% beat LENSAR's return on equity of -56.16%.
Company Gross Margin Earnings Per Share Invested Capital INBSIntelligent Bio Solutions39.76% -$8.40 $6.4M LNSRLENSAR46.28% -$0.13 $22.7M -
What do Analysts Say About INBS or LNSR?
Intelligent Bio Solutions has a consensus price target of --, signalling upside risk potential of 802.26%. On the other hand LENSAR has an analysts' consensus of -- which suggests that it could grow by 42.86%. Given that Intelligent Bio Solutions has higher upside potential than LENSAR, analysts believe Intelligent Bio Solutions is more attractive than LENSAR.
Company Buy Ratings Hold Ratings Sell Ratings INBSIntelligent Bio Solutions0 0 0 LNSRLENSAR0 0 0 -
Is INBS or LNSR More Risky?
Intelligent Bio Solutions has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock INBS or LNSR?
Intelligent Bio Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intelligent Bio Solutions pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INBS or LNSR?
Intelligent Bio Solutions quarterly revenues are $872.3K, which are smaller than LENSAR quarterly revenues of $13.5M. Intelligent Bio Solutions's net income of -$2.7M is lower than LENSAR's net income of -$1.5M. Notably, Intelligent Bio Solutions's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intelligent Bio Solutions is 0.62x versus 1.80x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INBSIntelligent Bio Solutions0.62x -- $872.3K -$2.7M LNSRLENSAR1.80x -- $13.5M -$1.5M
-
Which has Higher Returns INBS or ZOM?
Zomedica has a net margin of -307.88% compared to Intelligent Bio Solutions's net margin of -95.71%. Intelligent Bio Solutions's return on equity of -176.44% beat Zomedica's return on equity of -27.17%.
Company Gross Margin Earnings Per Share Invested Capital INBSIntelligent Bio Solutions39.76% -$8.40 $6.4M ZOMZomedica72.32% -$0.01 $202.8M -
What do Analysts Say About INBS or ZOM?
Intelligent Bio Solutions has a consensus price target of --, signalling upside risk potential of 802.26%. On the other hand Zomedica has an analysts' consensus of -- which suggests that it could grow by 99.52%. Given that Intelligent Bio Solutions has higher upside potential than Zomedica, analysts believe Intelligent Bio Solutions is more attractive than Zomedica.
Company Buy Ratings Hold Ratings Sell Ratings INBSIntelligent Bio Solutions0 0 0 ZOMZomedica0 0 0 -
Is INBS or ZOM More Risky?
Intelligent Bio Solutions has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zomedica has a beta of 1.044, suggesting its more volatile than the S&P 500 by 4.385%.
-
Which is a Better Dividend Stock INBS or ZOM?
Intelligent Bio Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zomedica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intelligent Bio Solutions pays -- of its earnings as a dividend. Zomedica pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INBS or ZOM?
Intelligent Bio Solutions quarterly revenues are $872.3K, which are smaller than Zomedica quarterly revenues of $7M. Intelligent Bio Solutions's net income of -$2.7M is higher than Zomedica's net income of -$6.7M. Notably, Intelligent Bio Solutions's price-to-earnings ratio is -- while Zomedica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intelligent Bio Solutions is 0.62x versus 4.59x for Zomedica. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INBSIntelligent Bio Solutions0.62x -- $872.3K -$2.7M ZOMZomedica4.59x -- $7M -$6.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
